1-6 of 6
Meredith Little, MPH
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Joseph M. Connors, MD, Árpád Illés, MD PhD, Marco Picardi, MD, Ewa Lech-Marańda, MD PhD, Tatyana Feldman, Piotr Smolewski, MD PhD, Kerry J. Savage, MDMSc, Nancy L. Bartlett, MD, Jan Walewski, MD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD, Martin Hutchings, MD PhD, Javier Munoz, MD, Won Seog Kim, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Anas Younes, Andrea Gallamini, Rachael Liu, PhD, Meredith Little, MPH, Keenan Fenton, Michelle A. Fanale, MD, John A. Radford, MD FMedSci
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-137089
Published: 2020
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018
Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Steven M. Horwitz, MD, Owen A. O'Connor, MD, PhD, Barbara Pro, MD, Tim M. Illidge, MDPhD, Michelle A. Fanale, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, MD PhD, Tatyana A. Feldman, MD, Anne Lennard, MBBS,FRCP, FRCPath, David Belada, MD PhD, Árpád Illés, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R. Shustov, MD, Andreas Hüttmann, MD, Kerry J Savage, BSc, MD MSc, Sam Yuen, Pier Luigi Zinzani, MD, Zhaowei Hua, Meredith Little, MPH, Shangbang Rao, PhD, Joseph Woolery, PharmD, Thomas Manley, MD, Lorenz Trümper, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 997.
https://doi.org/10.1182/blood-2018-99-110563
Published: 2018
Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Steven M. Horwitz, MD, Julia J. Scarisbrick, MD FRCP, MBBS †, Reinhard Dummer, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Jan Walewski, MD, Sean Whittaker, MB, ChB, FRCP, MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Jose A. Sanches, PhD, Pablo L. Ortiz-Romero, MD PhD, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, FRACP,FRCPA,MBBS, Stephane Dalle, MD PhD, Michael Weichenthal, MD, David C. Fisher, MD, Rudolf Stadler, MD, Tatyana A Feldman, MD, Timothy M. Kuzel, MD, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Meredith Little, MPH, H. Miles Prince, MD FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1509.
https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509
Published: 2017
Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD
Journal: Blood
Blood (2016) 128 (22): 182.
https://doi.org/10.1182/blood.V128.22.182.182
Published: 2016